DJIA 16,461.32 -153.49 -0.92%
NASDAQ 4,382.85 -36.63 -0.83%
S&P 500 1,927.11 -14.17 -0.73%
market minute promo

Durata Therapeutics (NASDAQ: DRTX)

23.82 -0.27 (-1.12%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

DRTX $23.82 -1.12%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $23.90
Previous Close $24.09
Daily Range $23.81 - $24.06
52-Week Range $8.92 - $24.33
Market Cap $637.8M
P/E Ratio -10.04
Dividend (Yield) $0.00 (0.0%)
Volume 305,751
Average Daily Volume 855,911
Current FY EPS -$2.88

Sector

Healthcare

Industry

Drugs

Durata Therapeutics (DRTX) Description

Durata Therapeutics Inc. is a pharmaceutical company focused on the development and commercialization of novel therapeutics for patients with infectious diseases and acute illnesses. Website: http://www.duratatherapeutics.com/

News & Commentary

Actavis plc and Valeant Pharmaceuticals Inc. Battle for Allergan Inc.: Who Wins?

Valeant Pharmaceuticals upped its bid offer for Botox maker Allergan by $15 a share yesterday. Actavis reportedly responded with an even richer offer. Will activist investor Bill Ackman get his way or will six months of work go down the drain?

Benzinga's Top Downgrades

Roth Capital Downgrades Durata Therapeutics To Neutral

Merger Arbitrage Mondays - October 13, 2014

Durata Offers New Data for DALVANCE, Patients Given DALVANCE Showed Fewer Adverse Events

Actavis in Acquisition Mode, Durata Deal to Boost Portfolio - Analyst Blog

Actavis Finds Rx To Grow On Busy Drugmaker M&A Scene

Stock Market News for October 07, 2014 - Market News

Market News: Advanced Technologies, Durata Therapeutics, Unilife

Sector Update: Health Care Stocks Drifting Lower; Durata Therapeutics Climbs to Record High Followin

Sector Update: Health Care Stocks Drifting Lower; Durata Therapeutics Climbs to Record High Following Actavis Buyout Offer

See More DRTX News...